C7 - C7 complement C7 Gene
生物種: Rattus norvegicus
遺伝子タイプ: protein coding
遺伝子ID: 117517
Summary
Involved in cellular sodium ion homeostasis. Predicted to be located in extracellular region. Predicted to be part of membrane attack complex. Used to study visual Epilepsy. Biomarker of membranous glomerulonephritis and Myocardial Infarction. Human ortholog(s) of this gene implicated in Complement Component 7 deficiency. Orthologous to human C7 (complement C7). [provided by Alliance of Genome Resources, Apr 2022]
C7 Products (1)
| mRNA | Protein | Name |
|---|---|---|
| XM_039103524.1 | XP_038959452.1 | LOW QUALITY PROTEIN: complement component C7 |
| Biological Process GO Annotation | Evidence | 参考文献 | 由来 |
|---|---|---|---|
| involved in intracellular sodium ion homeostasis |
IMP
IMP: Inferred from mutant phenotype
|
10792960 | RGD |
EXP: Inferred from Experiment
IDA: Inferred from direct assay
IPI: Inferred from physical interaction
IMP: Inferred from mutant phenotype
IGI: Inferred from genetic interaction
IEP: Inferred from expression pattern
| Protein Preferred Names | Protein Names | |
|---|---|---|
|
complement component C7 LOW QUALITY PROTEIN: complement component C7 |
|
|
Related Agents
- Approval
- Clinical Phase
- Pre-clinical Phase
Approval
Clinical Phase
Pre-clinical Phase
Bioactive Molecules
(104)
| 製品番号 | 製品名 |
製品効果
|
純度 |
Rare Diseases
|
|---|---|---|---|---|
| HY-150745A | ODN 24987 sodium | 99.08% | Unkown | |
| HY-120991 | 1-Palmitoyl-2-linoleoyl-sn-glycero-3-PE | 98.0% | Unkown | |
| HY-W088194 | Boc-C7-COOH | 99.33% | Unkown | |
| HY-W668775 | Quin-C7 | Antagonist | 99.76% | Unkown |
| HY-148671 | (S,R,S)-AHPC-amido-C7-acid | 98.71% | Unkown | |
| HY-150746A | ODN 24991 sodium | 99.64% | Unkown | |
| HY-161766 | L687 | Activator | 99.49% | Unkown |
| HY-W008821 | 1,7-Heptanediamine | Inhibitor | ≥98.0% | Unkown |
| HY-149577 | EBV lytic cycle inducer-1 | Inducer | 96.25% | Unkown |
| HY-147128 | PY109 | Agonist | 99.15% | Unkown |
| HY-P10501A | FRα-targeting peptide C7 TFA | 99.85% | Unkown | |
| HY-133799 | Pomalidomide-C7-COOH | 95.35% | Unkown | |
| HY-136005 | VH032-C7-COOH | 99.92% | Unkown | |
| HY-150746 | ODN 24991 | Inhibitor | 99.64% | Unkown |
| HY-B0315S | Vitamin B12-13C7 | 96.14% | Unkown | |
| HY-P3801 | [Glp5,(Me)Phe8,Sar9] Substance P (5-11) | Modulator | 99.61% | Unkown |
| HY-W012340S | H-HomoArg-OH-13C7,15N4 hydrochloride | Inhibitor | 98.0% | Unkown |
| HY-130640 | (S,R,S)-AHPC-Me-C7 ester | 95.49% | Unkown | |
| HY-131874 | Thalidomide-O-C7-acid | Inducer | 98.55% | Unkown |
| HY-131878 | Pomalidomide-C7-NH2 hydrochloride | 98.97% | Unkown | |
| HY-150745 | ODN 24987 | Inhibitor | / | Unkown |
| HY-163678 | Pomalidomide-CO-C7-NH-CO-C3-COOH | 98.55% | Unkown | |
| HY-16676 | 7-Epi-docetaxel | Activator | 98.76% | Unkown |
| HY-176224 | Anti-virulence factor-IN-2 | Inhibitor | 98.41% | Unkown |
| HY-P10501 | FRα-targeting peptide C7 | / | Unkown | |
| HY-RS03384 | CXCL10 Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-W011103 | Diheptyl phthalate | 98.64% | Unkown | |
| HY-W016087 | Monoethyl pimelate | / | Unkown | |
| HY-130949B | Thalidomide-4-O-C7-NH2 hydrochloride | 99.80% | Unkown | |
| HY-N6802 | Tigloylgomisin H | Inducer | 98.37% | Unkown |
| HY-130949 | Thalidomide-4-O-C7-NH2 | Inducer | / | Unkown |
| HY-128746S | 2,6-Diaminoheptanedioic acid-13C7,15N2 | / | Unkown | |
| HY-131622S | 7-Aminoclonazepam-13C6 | / | Unkown | |
| HY-131740 | 2'-Deoxytubercidin 5'-triphosphate | / | Unkown | |
| HY-131740A | 2'-Deoxytubercidin 5'-triphosphate sodium | / | Unkown | |
| HY-136186 | (S,R,S)-AHPC-C7-amine | / | Unkown | |
| HY-136186B | (S,R,S)-AHPC-C7-amine hydrochloride | / | Unkown | |
| HY-149564 | Thalidomide-5-O-C7-NH2 hydrochloride | Inducer | 98.13% | Unkown |
| HY-149645 | CB2 receptor antagonist 2 | Antagonist | / | Unkown |
| HY-151274 | SARS-CoV-2-IN-28 | Inhibitor | / | Unkown |
| HY-151274A | SARS-CoV-2-IN-28 disodium | Inhibitor | / | Unkown |
| HY-151468 | AIE-Cbz-LD-C7 | / | Unkown | |
| HY-153541 | AP-C7 | Inhibitor | / | Unkown |
| HY-155263 | Pomalidomide-5-C7-NH2 hydrochloride | / | Unkown | |
| HY-155527 | SARS-CoV-2 Mpro-IN-9 | Inhibitor | 99.31% | Unkown |
| HY-155560 | Pomalidomide-C7-NH2 | / | Unkown | |
| HY-157437 | AChE/BChE-IN-16 | Inhibitor | / | Unkown |
| HY-157883 | C7BzO | Inhibitor | / | Unkown |
| HY-161379 | CLZX-205 | Inhibitor | / | Unkown |
| HY-161663 | Phosphodiesterase-IN-2 | Inhibitor | / | Unkown |
| HY-161933 | 1-Adamantane-amide-C7-NH2 | / | Unkown | |
| HY-163758 | COOH-C3-CONH-C7-COOH | / | Unkown | |
| HY-163984 | Antibacterial agent 240 | Inhibitor | / | Unkown |
| HY-164799 | FXR agonist 12 | Agonist | / | Unkown |
| HY-167694 | Antiproliferative agent-62 | Activator | / | Unkown |
| HY-169006 | Evo312 | / | Unkown | |
| HY-173580 | 7-Deaza-2'-deoxyadenosine-5'-O-triphosphate tetrasodium | / | Unkown | |
| HY-174869 | Pomalidomide-5-C7-NH2 | / | Unkown | |
| HY-175241 | T-01-C7-amide | / | Unkown | |
| HY-176470 | Thalidomide-N-C-piperidine-C7-Br | / | Unkown | |
| HY-179720 | TT-012-NH-C7-NHBoc | / | Unkown | |
| HY-181189 | Lenalidomide-C7-NH2 | / | Unkown | |
| HY-181868 | Lenalidomide-CO-C7-NH2 | / | Unkown | |
| HY-181882 | MV78-OH-C7-COOH | / | Unkown | |
| HY-186154 | Thalidomide-amine-C7-acid | / | Unkown | |
| HY-187177 | Pomalidomide-C2-NHCO-C7-NHBoc | / | Unkown | |
| HY-CE01248 | C7:0-CoA | / | Unkown | |
| HY-E71528 | 2-epi-5-epi-Valiolone synthase | / | Unkown | |
| HY-N19150 | Cordybislactone hydrolyzed derivative-1 | / | Unkown | |
| HY-N21623 | Bambulignan B | / | Unkown | |
| HY-N6779S | Patulin-13C7 | / | Unkown | |
| HY-N7777 | 7-Xylosyl-10-Deacetyltaxol C | / | Unkown | |
| HY-P3972 | H-ILE-ARG-VAL-VAL-MET-OH | / | Unkown | |
| HY-RS01753 | C7 Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS01754 | C7orf50 Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS05971 | H3C7 Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS12598 | SDR9C7 Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-W142432S | Perfluoroundecanoic acid-13C7 | / | Unkown | |
| HY-W334800S | (2S,6S)-2,6-Diaminoheptanedioic acid-13C7,15N2 | / | Unkown | |
| HY-W334800S2 | (2S,6S)-2,6-Diaminoheptanedioic acid-13C7 | / | Unkown | |
| HY-W753671 | 2,6-Diaminoheptanedioic acid-13C7 | / | Unkown | |
| HY-W767186 | D-Mannoheptulose-13C7 | / | Unkown | |
| HY-W940797 | Thalidomide-O-amido-C7-NH2 | / | Unkown | |
| HY-Y1027S | 2-Chlorobenzoic Acid-13C7 | / | Unkown | |
| HY-100807S1 | Quinolinic acid-13C7 | / | Unkown | |
| HY-103447S2 | Zearalenone-13C7 | Activator | / | Unkown |
| HY-118051 | LY 186826 | / | Unkown | |
| HY-133698 | Lenalidomide-O-C7-COOH | / | Unkown | |
| HY-136186A | (S,R,S)-AHPC-C7-amine dihydrochloride | / | Unkown | |
| HY-14283S | Luliconazole-13C7 | / | Unkown | |
| HY-159204 | 3'-Amino-Modifier C7 CPG 1000 | / | Unkown | |
| HY-162862 | JAK-IN-38 | Inhibitor | / | Unkown |
| HY-180442 | 7-BioQ | / | Unkown | |
| HY-181356 | (S,R,S,R)-AHPC-Me-CO-C7-N3 | / | Unkown | |
| HY-185909 | Dodecanamido C7 Phosphoramidite | / | Unkown | |
| HY-185910 | Palmitamido C7 Phosphoramidite | / | Unkown | |
| HY-B0495S8 | Lamotrigine-13C7,15N | / | Unkown | |
| HY-RS16518 | Cxcl10 Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS17240 | C7 Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS20317 | Oxr1 Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS23694 | C7 Rat Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-W278073 | RNA splicing modulator 6 | Modulator | / | Unkown |
| HY-W800743 | Heptyl 6-bromohexanoate | / | Unkown | |
| HY-W939883 | Thalidomide-4-O-C7-Br | / | Unkown |
阻害性抗体
(3)
| 製品番号 | 製品名 |
製品効果
|
純度 |
Rare Diseases
|
|---|---|---|---|---|
| HY-P991608 | CTM01 | Inhibitor | 99.32% | Unkown |
| HY-P991573 | Anti-EGFR Antibody (D2C7) | Inhibitor | / | Unkown |
| HY-P991857 | Anti-Human/Mouse/Bovine ADAM10 Antibody (8C7) | 99.50% | Unkown |
Compound Screening Libraries
Virtual Screening
Customize Your Library
Drug Screening Service